Skin Cancer VA Rating

Skin cancer at the BVA tells a counterintuitive story. Most veterans filing skin cancer claims assume the Agent Orange presumption covers them, they were exposed to herbicides, herbicides cause cancer, therefore the cancer is presumed service-connected. That logic is intuitive and partially right. But it doesn't fit how 38 CFR § 3.309(e) actually reads.

The herbicide presumption in 38 USC § 1116 and 38 CFR § 3.309(e) covers specific diseases. Notably absent from both disease lists are basal cell carcinoma, cutaneous squamous cell carcinoma, and melanoma. Melanoma does have a separate toxic-exposure presumption under 38 USC §§ 1119 and 1120 for a covered veteran, and VA treats skin cancers of the head and neck as head or neck cancers under the same law, but those are not Agent Orange presumptions.

A ruling is one issue the Board decided in one decision; one decision often rules on several issues. In the Board's 2021 to 2026 service connection rulings on skin cancer, claims argued under a presumption were granted less often than claims argued as direct service connection. The Board section below shows both. A presumption helps only when it applies: when a veteran files under a presumption that doesn't cover the cancer or the service, the Board has to deny the presumptive theory even when the underlying condition is real and clearly related to sun exposure during service. The direct lane, by contrast, can succeed when the medical evidence establishes that in-service sun exposure (combined sometimes with other carcinogenic exposures) caused the eventual skin cancer.

TL;DR

• Across 4,296 decided Board rulings on skin cancer from 2021 to 2026, 23.4% were granted, 23.5% denied and 53.0% remanded. The remand rate is high, 7.7 points above the Board-wide 45.3 percent, and more than half of these rulings went back for additional development before a final decision.
• Skin cancer rates under several diagnostic codes depending on type and treatment. DC 7818 covers malignant skin neoplasms generally (excluding melanoma); DC 7833 covers melanoma. The 100% treatment rating applies only when therapy is comparable to treatment for a systemic malignancy. Treatment confined to the skin does not receive that automatic 100%.
• The Agent Orange presumption does not cover basal cell carcinoma, squamous cell carcinoma, or melanoma. It covers only specific named cancers under 38 CFR § 3.309(e). Veterans filing skin cancer claims under the herbicide presumption usually fail on the presumptive theory.
• For a covered veteran, the PACT Act presumes melanoma anywhere on the body, and VA treats basal cell and squamous cell carcinoma of the head or neck as head or neck cancers. The same cancers elsewhere on the body are not presumed.
• Sun exposure during service is the medically supported direct nexus theory for most skin cancers. Veterans with documented outdoor service (infantry, aviation, naval surface, certain MOS categories) can establish direct service connection when the nexus opinion engages with the cumulative UV exposure framework.
• The medical opinion the Board credits decides most of these claims. The Board section below shows how the Board ruled when it relied on a favorable opinion, an opinion against the claim, or none.
• Many veterans land at 0 percent after treatment because skin cancer residuals (scarring) don't always clear the rating thresholds. Appeals for a higher skin cancer rating were granted less often than service connection appeals.

Skin cancer VA rating criteria (DC 7818, 7833 and the scar codes)

Skin cancer ratings depend on which type of skin cancer and which body areas are involved. The framework lives in 38 CFR § 4.118 (the skin chapter).

DC 7818: basal cell and squamous cell carcinoma

This is the catch-all for basal cell carcinoma, squamous cell carcinoma, and other non-melanoma skin cancers. The structure is as follows.

• Ordinarily rate disfigurement of the head, face or neck (DC 7800), scars (DCs 7801 to 7805), or impairment of function.
• 100% only when treatment is comparable to therapy for a systemic malignancy, such as systemic chemotherapy, X-ray therapy more extensive than to the skin, or surgery more extensive than wide local excision.
• When that 100% rule applies, a mandatory examination follows six months after treatment ends; if there is no recurrence or metastasis, rate the residuals.
• If treatment is confined to the skin, the 100% treatment rule does not apply.

DC 7833: melanoma VA rating

DC 7833 uses the same distinction as DC 7818: rate scars, disfigurement, or functional impairment unless the melanoma requires therapy comparable to treatment for a systemic malignancy. Only that systemic-level therapy triggers the 100 percent rating and six-month re-evaluation rule. Treatment confined to the skin does not.

DC 7800: scars on the head, face or neck

This is where many post-treatment skin cancer ratings land. The criteria turn on visible or palpable tissue loss with distortion or asymmetry of features, or on the number of eight characteristics of disfigurement: a scar 5 or more inches long, a scar at least a quarter inch wide, an elevated or depressed surface contour, a scar adherent to underlying tissue, and, each over more than six square inches, abnormal pigmentation, abnormal skin texture, missing underlying soft tissue, or skin that is indurated and inflexible.

• 10%: One characteristic of disfigurement
• 30%: Visible or palpable tissue loss and either gross distortion or asymmetry of one feature, OR two or three characteristics of disfigurement
• 50%: Visible or palpable tissue loss and either gross distortion or asymmetry of two features, OR four or five characteristics of disfigurement
• 80%: Visible or palpable tissue loss and either gross distortion or asymmetry of three or more features, OR six or more characteristics of disfigurement

Pain, instability and nerve or muscle damage from a head, face or neck scar are rated separately and combined.

DCs 7801 to 7805: scars elsewhere on the body

Scars off the head, face and neck rate by area and by whether they are painful or unstable. A scar with underlying soft tissue damage needs at least 6 square inches for 10 percent under DC 7801, and the ladder runs to 40 percent at 144 square inches or more. One or two painful or unstable scars rate 10 percent under DC 7804. Most skin cancer scars on the body rate at 10 or 0 percent unless they're particularly large or symptomatic.

Is skin cancer presumptive from Agent Orange?

No. The herbicide disease lists in 38 USC § 1116 and 38 CFR § 3.309(e) are specific, not open-ended cancer categories. They include cancers such as these.

• Chronic B-cell leukemias
• Hodgkin's disease
• Multiple myeloma
• Non-Hodgkin's lymphoma
• Prostate cancer
• Respiratory cancers (lung, larynx, trachea, and bronchus)
• Soft-tissue sarcomas (other than osteosarcoma, chondrosarcoma, Kaposi's sarcoma, and mesothelioma)

Notably absent from the herbicide presumption: basal cell carcinoma, cutaneous squamous cell carcinoma, and melanoma. The statute and regulation do not presume those diseases based on herbicide exposure. One rare skin tumor is the exception: dermatofibrosarcoma protuberans is named in § 3.309(e) as a soft-tissue sarcoma.

This creates a recurring failure pattern in Board decisions. A Vietnam-era veteran files a claim for basal cell carcinoma asserting Agent Orange presumption. The C&P examiner notes the cancer type. The rating decision denies the presumption because the cancer isn't listed. The veteran appeals. The Board affirms the denial on the presumption theory but sometimes remands or grants on the direct theory if the medical evidence supports cumulative sun exposure during service. That is why claims argued under a presumption do worse at the Board than direct claims for skin cancer.

PACT Act skin cancer: melanoma anywhere, other skin cancers on the head or neck

The PACT Act's broad disease authority is 38 USC § 1120, applied to a covered veteran under § 1119. Section 1120 expressly lists melanoma. It does not list basal cell carcinoma or generic cutaneous squamous cell carcinoma by name, but it does list head cancer of any type and neck cancer of any type.

VA's PACT Act claims guidance spells out what that means for skin. VBA Letter 20-22-10 (December 2022) and its June 2024 update, VBA Letter 20-24-06, say that skin cancers other than melanoma qualify for the presumption only if the cancer is on the head or neck, and that all melanomas qualify regardless of location. The 2022 letter defines head cancers as malignancies of the scalp, face, mouth, ear areas, lips, and hard or soft palate, and lists basal cell and squamous cell carcinoma of the skin among its examples of both head and neck cancers. A basal or squamous cell carcinoma elsewhere on the body, such as the back or an arm, is not covered by those categories.

Section 3.320 does not supply a generic skin-cancer presumption. Its squamous-cell entries are squamous cell carcinoma of the larynx and trachea, not skin. Covered toxic exposure may still support direct service connection for a nonlisted skin cancer and may trigger development under 38 USC § 1168, but exposure alone is not the disease nexus.

Camp Lejeune, radiation and skin cancer

Camp Lejeune contaminated water: The disability presumption uses the qualifying-service rule in 38 CFR § 3.307(a)(7) and the disease list in § 3.309(f). That list does not include basal cell carcinoma, cutaneous squamous cell carcinoma, or melanoma. A Camp Lejeune exposure theory for skin cancer therefore needs a direct nexus; a separate presumptive disease supports a secondary claim only when medical evidence actually connects the two conditions.

Radiation exposure (38 CFR § 3.311): Skin cancer is listed as a radiogenic disease, but § 3.311 is a dose-development and adjudication procedure, not an automatic service-connection presumption. Skin cancer is not one of the diseases named in the separate radiation presumption at § 3.309(d).

Skin cancer from sun exposure in service

The medically supported direct service connection theory for most skin cancers is cumulative UV exposure. Occupational sun exposure is a well-studied risk factor for skin cancer, and a 2018 systematic review of skin cancer in the US military found that service in tropical environments was associated with more melanoma and non-melanoma skin cancer among World War II soldiers, with several studies pointing to sun exposure and too little sun protection during service (Riemenschneider, Journal of the American Academy of Dermatology). The review also noted that the studies' results vary.

For veterans pursuing the direct theory, the nexus opinion has to do specific work.

• Establish the cumulative UV exposure during service
• Establish that the exposure was significant enough to be a substantial contributing factor
• Address competing post-service exposures (occupational outdoor work, recreational sun exposure)
• Connect the exposure to the specific cancer type and location

The strongest direct-lane cases have veterans with documented outdoor MOS categories, infantry in tropical or desert deployments, aviation, naval surface, construction battalions, military police with extensive outdoor patrol. The location of the cancer on the body matters too. Cancers on the head, face, neck, ears, forearms, and back of the hands are anatomically consistent with sun exposure. Cancers on areas not typically sun-exposed (chest, abdomen, back, lower extremities) are harder to attribute to UV exposure alone.

In the Board data, direct claims were granted more often than presumptive ones. The reason is that direct-lane cases that win are typically well-developed on the sun exposure theory, while presumptive-lane cases often fail because they're trying to invoke a presumption that doesn't cover the cancer type.

Skin cancer ratings after treatment: the six-month rule and scars

The six-month re-evaluation rule applies only when DC 7818 or DC 7833 first authorizes 100 percent because treatment is comparable to therapy for a systemic malignancy. When treatment is confined to the skin, that automatic 100 percent and six-month sequence does not apply. After qualifying systemic-level treatment, the post-treatment rating depends on recurrence, metastasis, and residuals.

For most basal cell carcinomas and squamous cell carcinomas treated with Mohs surgery or simple excision, the residual is a small scar. These scars often don't clear the rating thresholds under DC 7800-7805, and many veterans end up at 0 percent post-treatment. The 30 percent and 100 percent post-treatment ratings in the Board decisions I read usually involve veterans with multiple cancers, large excision sites with significant disfigurement, or melanoma with metastatic disease that re-triggers the active-treatment 100 percent rating.

The rating math at the post-treatment stage depends heavily on which body area was treated. Head, face, and neck scars (DC 7800) rate higher than scars elsewhere because the disfigurement criteria are more developed. A nose scar that is at least a quarter inch wide with a depressed contour has two characteristics of disfigurement, enough for 30 percent under DC 7800. The same scar on a forearm, if it is not painful or unstable, usually rates 0 percent, because a scar off the head, face and neck needs at least 6 square inches with underlying soft tissue damage to reach 10 percent under DC 7801.

Why VA denies skin cancer claims

Skin cancer claims are sent back more often than most. Across 4,296 decided Board rulings on skin cancer from 2021 to 2026, 23.4% were granted, 23.5% denied and 53.0% remanded. That grant rate is 1.3 points below the Board-wide 24.7 percent.

When the Board denies skin cancer service connection, it is usually over the link to service, and less often because no in-service exposure was shown. The patterns repeat.

A presumption that does not apply. The claim relies on Agent Orange for a basal cell or squamous cell carcinoma, or on the PACT Act for one on the back, chest or arm. The presumption fails, and if no direct theory was developed, the claim fails with it.

No documented sun exposure in service. The service records do not show outdoor duty, tropical or desert deployment, or sunburn treatment, and no one has described the exposure in a statement.

An opinion that ignores the rest of your life. The examiner points to decades of post-service sun, or the private opinion never addresses it. The Board weighs the opinion that deals with both.

A location that does not fit sun exposure. A cancer on skin that is usually covered is harder to tie to UV exposure in service.

Scars below the rating thresholds. For rating appeals, a small post-treatment scar often does not meet any DC 7800 to 7805 criteria, so the rating stays at 0 percent.

When the Board remands a skin cancer claim instead of deciding it, the most common reason is an inadequate VA exam or opinion, followed by records VA still had to get and claims that never had a VA exam. The Board section below shows the denial and remand reasons, how claims argued as direct and presumptive fared, and what the Board did with medical opinions.

Questions veterans ask about skin cancer

Is basal cell carcinoma a presumptive condition?

Only under the PACT Act, and only on the head or neck. VA's PACT Act guidance treats basal cell carcinoma of the head or neck as a head or neck cancer for a covered veteran. It is not on the Agent Orange list anywhere on the body.

Is melanoma presumptive for Agent Orange?

No. Melanoma is not on the Agent Orange list in 38 CFR § 3.309(e). It is presumptive under the PACT Act for a covered veteran, wherever it appears on the body.

What is the VA rating for basal cell carcinoma?

Basal cell carcinoma is rated under DC 7818 on its residuals: disfigurement of the head, face or neck, other scars, or loss of function. A rating of 100 percent applies only when treatment is comparable to therapy for a systemic cancer. Many veterans are rated 0 or 10 percent after treatment, and higher when a facial scar has several characteristics of disfigurement.

Does Mohs surgery get a 100 percent rating?

Usually not. Mohs surgery and simple excision are normally treatment confined to the skin, and DC 7818 says the 100 percent rule does not apply to that. The 100 percent rating needs therapy such as systemic chemotherapy, radiation more extensive than to the skin, or surgery more extensive than wide local excision.

Can sun exposure in service support a skin cancer claim?

Yes, as direct service connection. The claim needs evidence of the exposure, such as outdoor duty or deployments, and a medical opinion that weighs it against sun exposure after service and explains why the cancer's location fits.

Bottom Line

Skin cancer is rated under several diagnostic codes in 38 CFR § 4.118. DC 7818 covers non-melanoma skin cancers and DC 7833 covers melanoma. Both ordinarily rate scars, disfigurement, or functional impairment; 100 percent applies only when therapy is comparable to treatment for a systemic malignancy, and treatment confined to the skin does not qualify. The Agent Orange presumption does not cover basal cell carcinoma, cutaneous squamous cell carcinoma, or melanoma. For a covered veteran, 38 USC §§ 1119 and 1120 separately presume melanoma, and VA treats basal cell and squamous cell carcinoma of the head or neck as head or neck cancers; the same cancers elsewhere on the body are not presumed. Section 3.320's squamous-cell cancers are limited to the larynx and trachea. Most other skin-cancer claims require direct nexus evidence, such as a medically supported in-service UV or toxic-exposure theory.

Methodology and Limitations

• Data source: 38 CFR § 4.118 DC 7800 through DC 7833 (skin chapter), 38 USC § 1116 and 38 CFR § 3.309(e) (herbicide presumption), 38 USC §§ 1119 and 1120 (toxic-exposure presumptions for melanoma and for head and neck cancers), VBA Letter 20-22-10 (December 22, 2022) and VBA Letter 20-24-06 (June 12, 2024) on skin cancers and head and neck locations, 38 USC § 1168 (toxic-exposure examinations and opinions), 38 CFR §§ 3.307(a)(7) and 3.309(f) (Camp Lejeune), 38 CFR §§ 3.309(d) and 3.311 (radiation), Riemenschneider et al., "Skin cancer in the military," Journal of the American Academy of Dermatology (2018), read as a PubMed abstract, and Claim Raven's read of every Board decision from 2021 to 2026 that it holds: 511,036 decisions containing 1,378,030 rulings.
• Sample size: 4,624 Board rulings on skin cancer from 2021 to 2026, of which 4,296 were decided. Outcomes split granted 23.4% (1,007), denied 23.5% (1,011), remanded 53.0% (2,278). Claim theory (direct, secondary, presumptive) and medical-opinion tiers are coded from the Board's discussion in each decision and appear in the Board section, computed from the same data. Claim theory counts decided service connection rulings, remands included; medical-opinion tiers count only service connection rulings the Board granted or denied.
• Limitations: Presumptions apply only to diseases named in the controlling statute or regulation, including valid later additions. Veterans and the Board sometimes treat broader exposure-based theories under presumptive coding even when the specific cancer isn't on the named list; Claim Raven's coding reflects how the Board treated the case rather than whether the presumption legally applied. Sun exposure as a direct nexus theory is medically well-supported but the Board has been inconsistent about accepting it without specific service-record documentation. The post-treatment residuals rating depends on which body area and severity; this read does not code rating tiers, so this page gives no rating-tier distribution. These observations describe BVA patterns and are not predictions of individual outcomes, and Claim Raven is data analysis, not legal, medical, or VA-accredited advice.